CSPC Pharmaceutical Group (HKG:1093) said its cervical cancer drug received a Fast Track designation by the US Food and Drug Administration, according to a Wednesday filing with the Hong Kong bourse.
CRB-701, which recently completed enrollment in the dose escalation part of its Phase I clinical trial, is meant to treat relapsed or refractory metastatic cervical cancer, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。